A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial
A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial
Nilima Parry‐Jones, Nicholas Peckham, Stephen Jenkins, Jonathan Cook et al.
Citations
7 citations
Journal
The Lancet Haematology
Topics
Chronic Lymphocytic Leukemia Research
Field-Weighted Citation Impact (FWCI)
11.38
article
A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial
Nilima Parry‐Jones, Nicholas Peckham, Stephen Jenkins, Jonathan Cook, Paul Moss, Thomas Roberts, Nicolás Martínez‐Calle, Duncan Murray, Helen Parry, Piers Patten, Marie Hodges, Toby A. Eyre, Georgina Talbot, Vicki S Barber, Sam Scott, Adrian Shields, Brian J. Willett, Shankara Paneesha, Lelia Duley, Robbert Hoogeboom, Gratian Vandici, Farooq Wandroo, Abhishek Abhishek, Claire V. Hutchinson, Anne Francis, Neil Phillips, Earnest Heartin, Gareth Plested
article en
7 citations
Abstract
No abstract available for this paper.
Publication Tag
The Lancet HaematologyVol. 12(4)
Institutions
Nottingham University Hospitals NHS Trust (GB), University of Nottingham (GB), King's College London (GB), Sandwell & West Birmingham Hospitals NHS Trust (GB), University Hospitals of North Midlands NHS Trust (GB), Aneurin Bevan University Health Board (GB), University Hospitals Coventry and Warwickshire NHS Trust (GB), University of Oxford (GB), MRC University of Glasgow Centre for Virus Research (GB), University Hospitals Plymouth NHS Trust (GB), University of Birmingham (GB)